DrugPatentWatch Database Preview
Patent: 9,868,972
» See Plans and Pricing
Summary for Patent: 9,868,972
Title: | Hybrid suppressor tRNA for vertebrate cells |
Abstract: | This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in vertebrate cells. The components include orthogonal tRNA\'s, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNA\'s/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in vertebrate cells are also provided. The present invention provides vertebrate cells with translation components, e.g., pairs of orthogonal aminoacyl-tRNA synthetases (O-RSs) and orthogonal tRNA\'s (O-tRNA\'s) and individual components thereof, that are used in vertebrate protein biosynthetic machinery to incorporate an unnatural amino acid in a growing polypeptide chain, in a vertebrate cell. |
Inventor(s): | Tian; Feng (San Diego, CA), Norman; Thea (Clinton, WA), Chu; Stephanie (Simi Valley, CA) |
Assignee: | Ambrx,Inc. (La Jolla, CA) |
Application Number: | 14/820,318 |
Patent Claims: | see list of patent claims |
Details for Patent 9,868,972
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Baxter Hlthcare Corp | MYXREDLIN | insulin human | SOLUTION;INTRAVENOUS | 208157 | 001 | 2019-06-20 | Start Trial | Ambrx,Inc. (La Jolla, CA) | 2026-09-08 | RX | search | |
Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 004 | 2015-01-23 | Start Trial | Ambrx,Inc. (La Jolla, CA) | 2026-09-08 | RX | Orphan | search |
Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 003 | 2015-01-23 | Start Trial | Ambrx,Inc. (La Jolla, CA) | 2026-09-08 | RX | Orphan | search |
Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 002 | 2015-01-23 | Start Trial | Ambrx,Inc. (La Jolla, CA) | 2026-09-08 | RX | Orphan | search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 9,868,972
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 2008030613 | Start Trial |
United States of America | 2010159586 | Start Trial |
United States of America | 2017096696 | Start Trial |
United States of America | 9133495 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |